Future Perspectives of Anemia Management in Chronic Kidney Disease Using Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors

Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are such novel agents to treat anemia in CKD. They stimulate endogenous erythropoietin production via HIF activation and thereby induce erythropoiesis.